This company has been marked as potentially delisted and may not be actively trading.

Gritstone bio (GRTS) Competitors

GRTS vs. PHIO, AKAN, TRAW, CTXR, and BLRX

Should you be buying Gritstone bio stock or one of its competitors? The main competitors of Gritstone bio include Phio Pharmaceuticals (PHIO), Akanda (AKAN), Traws Pharma (TRAW), Citius Pharmaceuticals (CTXR), and BioLineRx (BLRX). These companies are all part of the "pharmaceutical products" industry.

How does Gritstone bio compare to Phio Pharmaceuticals?

Phio Pharmaceuticals (NASDAQ:PHIO) and Gritstone bio (NASDAQ:GRTS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

: Phio Pharmaceuticals has higher earnings, but lower revenue than Gritstone bio. Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Gritstone bio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Phio Pharmaceuticals N/A N/A -$8.70M -$1.45 N/A
Gritstone bio $496K 7.05 -$138.49M -$1.24 N/A
: 57.3% of Phio Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.5% of Gritstone bio shares are owned by institutional investors. 0.9% of Phio Pharmaceuticals shares are owned by insiders. Comparatively, 4.6% of Gritstone bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
: Phio Pharmaceuticals presently has a consensus price target of $14.00, suggesting a potential upside of 1,138.94%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Phio Pharmaceuticals is more favorable than Gritstone bio.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Phio Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Gritstone bio
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Phio Pharmaceuticals has a net margin of 0.00% compared to Gritstone bio's net margin of -910.50%. Phio Pharmaceuticals' return on equity of -66.59% beat Gritstone bio's return on equity.
Company Net Margins Return on Equity Return on Assets
Phio Pharmaceuticals N/A -66.59% -60.26%
Gritstone bio -910.50% -328.51% -82.53%
: In the previous week, Phio Pharmaceuticals' average media sentiment score of 0.00 equaled Gritstone bio'saverage media sentiment score.
Company Overall Sentiment
Phio Pharmaceuticals Neutral
Gritstone bio Neutral
: Phio Pharmaceuticals has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, Gritstone bio has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.45	N/A
Gritstone bio	$496K	7.05	-$138.49M	-$1.24	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gritstone bio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-66.59%	-60.26%
Gritstone bio	-910.50%	-328.51%	-82.53%

Company	Overall Sentiment
Phio Pharmaceuticals	Neutral
Gritstone bio	Neutral

Summary

Phio Pharmaceuticals beats Gritstone bio on 9 of the 13 factors compared between the two stocks.

How does Gritstone bio compare to Akanda?

Gritstone bio (NASDAQ:GRTS) and Akanda (NASDAQ:AKAN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

: Akanda has higher revenue and earnings than Gritstone bio.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gritstone bio $496K 7.05 -$138.49M -$1.24 N/A
Akanda $840K 18.93 -$4.10M N/A N/A
: 48.5% of Gritstone bio shares are held by institutional investors. Comparatively, 1.0% of Akanda shares are held by institutional investors. 4.6% of Gritstone bio shares are held by company insiders. Comparatively, 20.4% of Akanda shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gritstone bio
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Akanda
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Akanda has a net margin of 0.00% compared to Gritstone bio's net margin of -910.50%. Akanda's return on equity of 0.00% beat Gritstone bio's return on equity.
Company Net Margins Return on Equity Return on Assets
Gritstone bio -910.50% -328.51% -82.53%
Akanda N/A N/A N/A
: In the previous week, Akanda had 15 more articles in the media than Gritstone bio. MarketBeat recorded 15 mentions for Akanda and 0 mentions for Gritstone bio. Akanda's average media sentiment score of 0.12 beat Gritstone bio's score of 0.00 indicating that Akanda is being referred to more favorably in the news media.
Company Overall Sentiment
Gritstone bio Neutral
Akanda Neutral
: Gritstone bio has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, Akanda has a beta of 14.49, indicating that its share price is 1,349% more volatile than the S&P 500.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gritstone bio	$496K	7.05	-$138.49M	-$1.24	N/A
Akanda	$840K	18.93	-$4.10M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gritstone bio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Gritstone bio	-910.50%	-328.51%	-82.53%
Akanda	N/A	N/A	N/A

Company	Overall Sentiment
Gritstone bio	Neutral
Akanda	Neutral

Summary

Akanda beats Gritstone bio on 11 of the 12 factors compared between the two stocks.

How does Gritstone bio compare to Traws Pharma?

Traws Pharma (NASDAQ:TRAW) and Gritstone bio (NASDAQ:GRTS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

: Traws Pharma has a net margin of 0.00% compared to Gritstone bio's net margin of -910.50%. Traws Pharma's return on equity of 112.18% beat Gritstone bio's return on equity.
Company Net Margins Return on Equity Return on Assets
Traws Pharma N/A 112.18% 35.31%
Gritstone bio -910.50% -328.51% -82.53%
: Traws Pharma currently has a consensus target price of $8.00, indicating a potential upside of 406.33%. Given Traws Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Traws Pharma is more favorable than Gritstone bio.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Traws Pharma
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.50
Gritstone bio
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Traws Pharma has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Comparatively, Gritstone bio has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500.
: In the previous week, Traws Pharma had 4 more articles in the media than Gritstone bio. MarketBeat recorded 4 mentions for Traws Pharma and 0 mentions for Gritstone bio. Traws Pharma's average media sentiment score of 0.97 beat Gritstone bio's score of 0.00 indicating that Traws Pharma is being referred to more favorably in the media.
Company Overall Sentiment
Traws Pharma Positive
Gritstone bio Neutral
: 7.9% of Traws Pharma shares are owned by institutional investors. Comparatively, 48.5% of Gritstone bio shares are owned by institutional investors. 14.0% of Traws Pharma shares are owned by insiders. Comparatively, 4.6% of Gritstone bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: Traws Pharma has higher revenue and earnings than Gritstone bio. Gritstone bio is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Traws Pharma $2.79M 5.75 $9.17M $0.93 1.70
Gritstone bio $496K 7.05 -$138.49M -$1.24 N/A

Company	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	112.18%	35.31%
Gritstone bio	-910.50%	-328.51%	-82.53%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Gritstone bio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Overall Sentiment
Traws Pharma	Positive
Gritstone bio	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.79M	5.75	$9.17M	$0.93	1.70
Gritstone bio	$496K	7.05	-$138.49M	-$1.24	N/A

Summary

Traws Pharma beats Gritstone bio on 15 of the 17 factors compared between the two stocks.

How does Gritstone bio compare to Citius Pharmaceuticals?

Citius Pharmaceuticals (NASDAQ:CTXR) and Gritstone bio (NASDAQ:GRTS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

: Citius Pharmaceuticals has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Gritstone bio has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500.
: Citius Pharmaceuticals has a net margin of 0.00% compared to Gritstone bio's net margin of -910.50%. Citius Pharmaceuticals' return on equity of -49.34% beat Gritstone bio's return on equity.
Company Net Margins Return on Equity Return on Assets
Citius Pharmaceuticals N/A -49.34% -28.64%
Gritstone bio -910.50% -328.51% -82.53%
: Citius Pharmaceuticals currently has a consensus target price of $6.00, indicating a potential upside of 773.36%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Gritstone bio.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Citius Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Gritstone bio
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: In the previous week, Citius Pharmaceuticals had 4 more articles in the media than Gritstone bio. MarketBeat recorded 4 mentions for Citius Pharmaceuticals and 0 mentions for Gritstone bio. Citius Pharmaceuticals' average media sentiment score of 0.16 beat Gritstone bio's score of 0.00 indicating that Citius Pharmaceuticals is being referred to more favorably in the media.
Company Overall Sentiment
Citius Pharmaceuticals Neutral
Gritstone bio Neutral
: Citius Pharmaceuticals has higher revenue and earnings than Gritstone bio. Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Gritstone bio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Citius Pharmaceuticals $3.94M 3.90 -$37.43M -$2.45 N/A
Gritstone bio $496K 7.05 -$138.49M -$1.24 N/A
: 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.5% of Gritstone bio shares are owned by institutional investors. 5.0% of Citius Pharmaceuticals shares are owned by insiders. Comparatively, 4.6% of Gritstone bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-49.34%	-28.64%
Gritstone bio	-910.50%	-328.51%	-82.53%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gritstone bio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Overall Sentiment
Citius Pharmaceuticals	Neutral
Gritstone bio	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	$3.94M	3.90	-$37.43M	-$2.45	N/A
Gritstone bio	$496K	7.05	-$138.49M	-$1.24	N/A

Summary

Citius Pharmaceuticals beats Gritstone bio on 12 of the 16 factors compared between the two stocks.

How does Gritstone bio compare to BioLineRx?

BioLineRx (NASDAQ:BLRX) and Gritstone bio (NASDAQ:GRTS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

: BioLineRx has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, Gritstone bio has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500.
: 1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 48.5% of Gritstone bio shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by insiders. Comparatively, 4.6% of Gritstone bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
: BioLineRx has a net margin of -99.58% compared to Gritstone bio's net margin of -910.50%. BioLineRx's return on equity of -5.61% beat Gritstone bio's return on equity.
Company Net Margins Return on Equity Return on Assets
BioLineRx -99.58% -5.61% -2.81%
Gritstone bio -910.50% -328.51% -82.53%
: In the previous week, BioLineRx had 1 more articles in the media than Gritstone bio. MarketBeat recorded 1 mentions for BioLineRx and 0 mentions for Gritstone bio. Gritstone bio's average media sentiment score of 0.00 beat BioLineRx's score of -0.33 indicating that Gritstone bio is being referred to more favorably in the news media.
Company Overall Sentiment
BioLineRx Neutral
Gritstone bio Neutral
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLineRx
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.67
Gritstone bio
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: BioLineRx has higher revenue and earnings than Gritstone bio. BioLineRx is trading at a lower price-to-earnings ratio than Gritstone bio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioLineRx $1.18M 11.21 -$1.17M -$0.17 N/A
Gritstone bio $496K 7.05 -$138.49M -$1.24 N/A

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-99.58%	-5.61%	-2.81%
Gritstone bio	-910.50%	-328.51%	-82.53%

Company	Overall Sentiment
BioLineRx	Neutral
Gritstone bio	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Gritstone bio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	11.21	-$1.17M	-$0.17	N/A
Gritstone bio	$496K	7.05	-$138.49M	-$1.24	N/A

Summary

BioLineRx beats Gritstone bio on 12 of the 16 factors compared between the two stocks.

Get Gritstone bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRTS vs. The Competition

Export

Metric	Gritstone bio	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.50M	$328.15M	$6.25B	$11.87B
Dividend Yield	N/A	N/A	2.73%	5.21%
P/E Ratio	-0.03	N/A	29.04	28.47
Price / Sales	7.05	189.48	476.61	60.94
Price / Cash	N/A	22.44	27.62	36.52
Price / Book	0.06	4.73	9.67	6.67
Net Income	-$138.49M	-$132.96M	$3.55B	$332.53M

Gritstone bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRTS Gritstone bio	N/A	$0.03 flat	N/A	N/A	$3.50M	$496K	N/A	190
PHIO Phio Pharmaceuticals	2.8286 of 5 stars	$1.20 -0.4%	$14.00 +1,071.5%	N/A	$13.88M	N/A	N/A	10
AKAN Akanda	0.9663 of 5 stars	$26.01 +48.7%	N/A	N/A	$13.82M	$840K	N/A	110	Gap Down High Trading Volume
TRAW Traws Pharma	4.0883 of 5 stars	$1.36 +12.0%	$8.00 +490.4%	N/A	$13.76M	$2.79M	1.46	17	High Trading Volume
CTXR Citius Pharmaceuticals	1.5257 of 5 stars	$0.61 -6.0%	$6.00 +882.0%	N/A	$13.72M	$3.94M	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRTS) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gritstone bio (GRTS) Competitors

GRTS vs. PHIO, AKAN, TRAW, CTXR, and BLRX

How does Gritstone bio compare to Phio Pharmaceuticals?

Summary

How does Gritstone bio compare to Akanda?

Summary

How does Gritstone bio compare to Traws Pharma?

Summary

How does Gritstone bio compare to Citius Pharmaceuticals?

Summary

How does Gritstone bio compare to BioLineRx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRTS vs. The Competition

Gritstone bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gritstone bio (GRTS) Competitors

GRTS vs. PHIO, AKAN, TRAW, CTXR, and BLRX

How does Gritstone bio compare to Phio Pharmaceuticals?

Summary

How does Gritstone bio compare to Akanda?

Summary

How does Gritstone bio compare to Traws Pharma?

Summary

How does Gritstone bio compare to Citius Pharmaceuticals?

Summary

How does Gritstone bio compare to BioLineRx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRTS vs. The Competition

Gritstone bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools